Table 1.
Clinical utility of GADA (RBA and ECL) assays and demographics (BMI) for predicting early insulin treatment in two cohorts (Action LADA and DiYA). PPV and sensitivity as a marker of early insulin treatment. Whilst PPV with ECL-GADA is higher than with RBA-GADA it can be further enhanced in both cohorts using low BMI (<25 kg/m2)
| Action LADA | DiYA | |||
|---|---|---|---|---|
| Characteristic | PPV | Sensitivity | PPV | Sensitivity |
| BMI <25 kg/m2, n (%) | 55/166 (33.1) | 55/94 (58.5) | 39/127 (30.7) | 39/368 (10.6) |
| RBA-GADA+, n (%) | 70/249 (28.1) | 70/96 (72.9) | 43/125 (34.4) | 43/368 (11.7) |
| ECL-GADA+, n (%) | 64/171 (37.4) | 64/96 (66.7) | 40/98 (40.8) | 40/ 368 (10.9) |
| RBA-GADA+ & BMI < 25 kg/m2, n (%) | 47/111 (42.3) | 47/93 (50.5) | 21/36 (58.3) | 21/368 (5.7) |
| ECL-GADA+ & BMI < 25 kg/m2, n (%) | 43/94 (45.7) | 43/93 (46.2) | 21/38 (55.3) | 21/368 (5.7) |